A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.

Saved in:

Bibliographic Details
Title:	A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Authors:	Smith KER; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., Peng KW; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Pulido JS; Department of Ophthalmology, Wills Eye Hospital, Philadelphia, PA, United States., Weisbrod AJ; Department of Radiology, Mayo Clinic, Rochester, MN, United States., Strand CA; Department of Biostatistics and Informatics, Mayo Clinic, Rochester, MN, United States., Allred JB; Department of Biostatistics and Informatics, Mayo Clinic, Rochester, MN, United States., Newsom AN; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Zhang L; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Packiriswamy N; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Kottke T; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Tonne JM; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Moore M; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Montane HN; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., Kottschade LA; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., McWilliams RR; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., Dudek AZ; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., Yan Y; Department of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL, United States., Dimou A; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., Markovic SN; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States., Federspiel MJ; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Vile RG; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States., Dronca RS; Department of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL, United States., Block MS; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
Source:	Frontiers in immunology [Front Immunol] 2023 Oct 31; Vol. 14, pp. 1279387. Date of Electronic Publication: 2023 Oct 31 (Print Publication: 2023).
Publication Type:	Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2023.1279387